Showing results (291-300 of 319) with videos related to

Sort By:
Pageof 32
Cell|February 22, 2023
Bat pluripotent stem cells reveal unusual entanglement between host and virusesMarion Déjosez, Arturo Marin, Graham M Hughes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2024
Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk DiseaseMatthew S Davids, Christine E Ryan, Benjamin L Lampson, et al.
Nature Medicine|December 10, 2023
Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trialLihua E Budde, Adam J Olszewski, Sarit Assouline, et al.
Journal of Hematology & Oncology|May 9, 2023
Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite studyNarendranath Epperla, Rina Li Welkie, Pallawi Torka, et al.
Blood|September 15, 2018
Bone marrow-specific loss ofAnna Chorzalska, John Morgan, Nagib Ahsan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2025
Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO TrialLihua E Budde, Huilai Zhang, Won-Seog Kim, et al.
Medrxiv : the Preprint Server for Health Sciences|October 13, 2021
Acute COVID-19 gene-expression profiles show multiple etiologies of long-term sequelaeRyan C Thompson, Nicole W Simons, Lillian Wilkins, et al.
Nature Medicine|December 9, 2022
Molecular states during acute COVID-19 reveal distinct etiologies of long-term sequelaeRyan C Thompson, Nicole W Simons, Lillian Wilkins, et al.
Blood Advances|January 17, 2020
Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogeneticsPallawi Torka, Shalin K Kothari, Suchitra Sundaram, et al.
Blood Advances|February 23, 2022
An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphomaJuan Pablo Alderuccio, Luca Arcaini, Marcus P Watkins, et al.
Pageof 32